EP3525777A1 - Xanthohumol for use in treating haemorrhoidal disease - Google Patents

Xanthohumol for use in treating haemorrhoidal disease

Info

Publication number
EP3525777A1
EP3525777A1 EP17804652.0A EP17804652A EP3525777A1 EP 3525777 A1 EP3525777 A1 EP 3525777A1 EP 17804652 A EP17804652 A EP 17804652A EP 3525777 A1 EP3525777 A1 EP 3525777A1
Authority
EP
European Patent Office
Prior art keywords
xanthohumol
composition according
composition
weight
haemorrhoidal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17804652.0A
Other languages
German (de)
English (en)
French (fr)
Inventor
Malgorzata KRUSZEWSKA-GAGOS
Mariusz GAGOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioactive-Tech Sp Z OO
Original Assignee
Bioactive-Tech Sp Z OO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioactive-Tech Sp Z OO filed Critical Bioactive-Tech Sp Z OO
Publication of EP3525777A1 publication Critical patent/EP3525777A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/121Ketones acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)

Definitions

  • Haemorrhoids are commonly called haemorrhoids only when they cause haemorrhoidal ailments. They however remain unnoticed until they are of normal size and are able to perform their precise rectal closure function (F. H. Wullink, Hemoroidy. Poradnik dla pacjentow, 1st Polish edition, ed. K. Matysiak, Wroclaw 2008, pages 10-11.)
  • DC electrotherapy requires time-consuming (up to 14 minutes) DC applications. Time and intensity increase with the progression of piles. Repeated applications to the same place are recorded in 30% of patients.
  • Infrared photocoagulation focuses the infrared radiation from the halogen lamp through the polymer probe at its top.
  • the 0.5-2 second energy pulses are delivered to the base of the vascular bundle, which penetrate about 2.5 mm into the tissue.
  • the most effective method is rubber bands, and patients undergoing this procedure are least often treated for haemorrhoids. Unfortunately, this group of patients simultaneously reported most often pain after surgery. In conclusion it might be admitted that non-surgical methods may be considered as the initial procedures of choice in patients with grade I and II haemorrhoids and early, small piles in grade III.
  • composition of the invention is preferably in the form of a semi-solid such as an ointment or a cream, preferably comprising a petrolatum as a physiologically acceptable excipient.
  • the composition comprises xanthohumol in an amount ranging from 0.001% by weight to 5.0% by weight of xanthohumol in terms of the total weight of the composition, more preferably, the composition comprises xanthohumol in an amount ranging from 0.01% by weight to 1.0% by weight of xanthohumol in terms of the total weight of the composition, most preferably, the composition comprises xanthohumol in an amount ranging from 0.1 % by weight to 0.5% by weight of xanthohumol in terms of the total weight of the composition.
  • Xanthohumol also forms complexes with metals, especially with transition metals such as copper or zinc. Such xanthohumol complexes may also be used according to the invention.
  • compositions may also contain one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, matting agents, lubricants, processing aids, dyes, sweeteners, perfumes, flavours and other known additives providing an elegant presentation of the drug or helping in the manufacture of a pharmaceutical or cosmetic or care product (i.e. a drug, a medicinal preparation, a medical product, a cosmetic product).
  • a pharmaceutical or cosmetic or care product i.e. a drug, a medicinal preparation, a medical product, a cosmetic product.
  • composition of the invention may be advantageously administered as an ointment or suppositories, however, other pharmaceutical or cosmetic forms such as a cream, gel or spray or dusting powder, powder or wet wipe may also be convenient for the patient or the recipient of the product.
  • xanthohumol is effective and causes a gradual reversion of the symptoms of the haemorrhoidal disease to its complete disappearance even in the advanced grade of the haemorrhoidal disease.
  • xanthohumol has a regenerating, nourishing, antipruritic and care effect on the skin around the anus, eliminating burning sensation and soreness, resulting in a noticeable improvement and alleviation, especially in the case of irritation of the anus and and the anal area.
  • Embodiment 5 Use of xanthohumol in the anal area for the skin care purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP17804652.0A 2016-10-12 2017-10-12 Xanthohumol for use in treating haemorrhoidal disease Withdrawn EP3525777A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL419082A PL235226B1 (pl) 2016-10-12 2016-10-12 Ksantohumol do zastosowania w leczeniu lub zapobieganiu i profilaktyce chorób hemoroidalnych oraz kompozycja zawierająca ksantohumol
PCT/IB2017/056302 WO2018069855A1 (en) 2016-10-12 2017-10-12 Xanthohumol for use in treating haemorrhoidal disease

Publications (1)

Publication Number Publication Date
EP3525777A1 true EP3525777A1 (en) 2019-08-21

Family

ID=59684565

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17804652.0A Withdrawn EP3525777A1 (en) 2016-10-12 2017-10-12 Xanthohumol for use in treating haemorrhoidal disease

Country Status (3)

Country Link
EP (1) EP3525777A1 (pl)
PL (1) PL235226B1 (pl)
WO (1) WO2018069855A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL429672A1 (pl) * 2019-04-17 2020-10-19 Bioxan Spółka Z Ograniczoną Odpowiedzialnością Preparat zawierający ksantohumol i zastosowanie ksantohumolu

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103751717B (zh) * 2014-01-13 2015-11-18 李绍华 一种治疗痔疮的药物组合物
CN103845615B (zh) * 2014-03-24 2016-03-30 李周全 一种治疗阴道炎的药物组合物

Also Published As

Publication number Publication date
WO2018069855A1 (en) 2018-04-19
PL235226B1 (pl) 2020-06-15
PL419082A1 (pl) 2017-08-28

Similar Documents

Publication Publication Date Title
JP6778219B2 (ja) 皮膚の炎症を抑制するイガイ接着タンパク質製品及びその適用
US5504117A (en) Pharmacologic preparation for the treatment of anal disorders
HU211823A9 (en) Formulations containing hyaluronic acid
MXPA00009705A (es) Uso de poliaminas en el tratamiento de sintomas dermatologicos.
HU211689A9 (en) Treatment of disease employing hyaluronic acid and nsaids
JP6104390B2 (ja) ミクロスフェアを含む改良された創傷治癒用組成物
US20060240119A1 (en) Pharmacologically active strong acid solutions
US20210236446A1 (en) Wound healing composition
RU2433844C1 (ru) Способ лечения дегенеративно-дистрофических заболеваний опорно-двигательного аппарата и посттравматических болевых синдромов
WO2018069855A1 (en) Xanthohumol for use in treating haemorrhoidal disease
RU2318503C1 (ru) Способ лечения анальной трещины
RU2366648C2 (ru) Продукт взаимодействия двуокиси селена с алифатическими галоидкарбоновыми кислотами, способ получения продукта, раствор продукта и способ лечения доброкачественных, вирусных, предзлокачественных и злокачественных неметастазирующих поражений кожи, диспластических поражений видимых слизистых оболочек и иных поражений кожи
RU2538079C1 (ru) Композиция для лечения анальных трещин
TW202339711A (zh) 預防或治療心血管疾病的高穿透性的阿司匹靈和其他非類固醇抗發炎藥的前藥
RU2702347C2 (ru) Лечение или профилактика себорейного кератоза с применением артемизинина и его производных
CN100531727C (zh) 含有维生素k1氧化物或其衍生物的组合物用于治疗和/或预防哺乳动物皮肤损害的用途
RU2375054C2 (ru) Препарат для лечения поражений кожи, способ получения препарата (варианты) и способ лечения поражений кожи
RU2445100C2 (ru) Консервативный способ комплексного лечения острых и хронических анальных трещин
RU2595799C1 (ru) Композиция для лечения анальных трещин в форме крема
US20190365735A1 (en) Compositions and methods for treating varicose veins
CN108404094A (zh) 一种疏络止痛消炎蜂毒应用调理膏
Gallese Treatment Protocol of the Most Common Anorectal Pathologies with Association between Micronized Purified Flavonoid Fraction and Sucralfate for Local Appli-cation
CN117100818A (zh) 一种治疗痔疮的外用膏剂及其制备方法
CN116077523A (zh) 一种用于防治痔疮的组合物及其制备方法与应用
WO2015048930A1 (zh) 一种含氯诺昔康和聚维酮碘的药物组合物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190508

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220503